Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 397
- Registration Number
- NCT00004031
- Locations
- 🇨🇦
Moncton Hospital, Moncton, New Brunswick, Canada
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇨🇦Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 483
- Registration Number
- NCT00002995
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 147
- Registration Number
- NCT00040937
- Locations
- 🇺🇸
Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States
🇺🇸Community Medical Center, Missoula, Montana, United States
🇺🇸Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
- Conditions
- Interventions
- Biological: filgrastimDrug: docetaxelDrug: cyclophosphamideGenetic: microarray analysisDrug: epirubicin hydrochlorideDrug: fluorouracilOther: laboratory biomarker analysisOther: immunohistochemistry staining methodProcedure: biopsyProcedure: neoadjuvant therapyProcedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-24
- Target Recruit Count
- 1856
- Registration Number
- NCT00017095
- Locations
- 🇬🇧
Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom
🇵🇹Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A., Lisbon, Portugal
🇨🇭Inselspital Bern, Bern, Switzerland
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 77
- Registration Number
- NCT00004088
- Locations
- 🇺🇸
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 3871
- Registration Number
- NCT00041119
- Locations
- 🇺🇸
UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
🇺🇸Dubs Cancer Center at Rogue Valley Medical Center, Medford, Oregon, United States
Combination Chemotherapy in Treating Children With Neuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 573
- Registration Number
- NCT00003093
- Locations
- 🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
🇺🇸MBCCOP - Hawaii, Honolulu, Hawaii, United States
TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1148
- Registration Number
- NCT00002757
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇬🇧Children's Hospital - Sheffield, Sheffield, England, United Kingdom
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3436
- Registration Number
- NCT00005970
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Vermont and State Agricultural College, Burlington, Vermont, United States
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 87
- Registration Number
- NCT00005987
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.